Is ABEO or OMER more profitable?

Abeona Therapeutics' return on equity of -41.69% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -41.69% -30.36% Omeros N/A -164.92% 69.41%

Does the media refer more to ABEO or OMER?

In the previous week, Abeona Therapeutics had 2 more articles in the media than Omeros. MarketBeat recorded 6 mentions for Abeona Therapeutics and 4 mentions for Omeros. Omeros' average media sentiment score of 1.11 beat Abeona Therapeutics' score of 0.57 indicating that Omeros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MGTX or ABEO?

In the previous week, Abeona Therapeutics had 3 more articles in the media than MeiraGTx. MarketBeat recorded 6 mentions for Abeona Therapeutics and 3 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.70 beat Abeona Therapeutics' score of 0.57 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ORIC or ABEO more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Abeona Therapeutics N/A -41.69% -30.36%

Does the media favor ORIC or ABEO?

In the previous week, Abeona Therapeutics had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 6 mentions for Abeona Therapeutics and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.82 beat Abeona Therapeutics' score of 0.57 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ABEO or MNKD?

In the previous week, MannKind had 5 more articles in the media than Abeona Therapeutics. MarketBeat recorded 11 mentions for MannKind and 6 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.57 beat MannKind's score of 0.48 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Abeona Therapeutics (ABEO) Competitors

$5.41 -0.01 (-0.18%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$5.40 -0.01 (-0.18%)

As of 05:23 AM Eastern

Compare

ABEO vs. OMER, MGTX, ORIC, IMTX, and MNKD

Should you buy Abeona Therapeutics stock or one of its competitors? Abeona Therapeutics's main competitors and comparable companies include Omeros (OMER), MeiraGTx (MGTX), Oric Pharmaceuticals (ORIC), Immatics (IMTX), and MannKind (MNKD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Abeona Therapeutics compare to Omeros?

Abeona Therapeutics (NASDAQ:ABEO) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Abeona Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, Omeros has a beta of 2.6, suggesting that its share price is 160% more volatile than the broader market.

Abeona Therapeutics currently has a consensus target price of $19.33, indicating a potential upside of 257.36%. Omeros has a consensus target price of $38.00, indicating a potential upside of 107.88%. Given Abeona Therapeutics' higher probable upside, equities research analysts clearly believe Abeona Therapeutics is more favorable than Omeros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Abeona Therapeutics has higher revenue and earnings than Omeros. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	53.15	$71.18M	-$1.09	N/A
Omeros	N/A	N/A	-$3.35M	$1.28	14.28

In the previous week, Abeona Therapeutics had 2 more articles in the media than Omeros. MarketBeat recorded 6 mentions for Abeona Therapeutics and 4 mentions for Omeros. Omeros' average media sentiment score of 1.11 beat Abeona Therapeutics' score of 0.57 indicating that Omeros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omeros	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abeona Therapeutics' return on equity of -41.69% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
Omeros	N/A	-164.92%	69.41%

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by company insiders. Comparatively, 10.5% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Omeros beats Abeona Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Abeona Therapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MeiraGTx has a net margin of 19.87% compared to Abeona Therapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Abeona Therapeutics	N/A	-41.69%	-30.36%

Abeona Therapeutics has lower revenue, but higher earnings than MeiraGTx. Abeona Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	15.09	-$114.20M	$0.71	18.01
Abeona Therapeutics	$5.82M	53.15	$71.18M	-$1.09	N/A

MeiraGTx currently has a consensus target price of $26.17, indicating a potential upside of 104.59%. Abeona Therapeutics has a consensus target price of $19.33, indicating a potential upside of 257.36%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

MeiraGTx has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

In the previous week, Abeona Therapeutics had 3 more articles in the media than MeiraGTx. MarketBeat recorded 6 mentions for Abeona Therapeutics and 3 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.70 beat Abeona Therapeutics' score of 0.57 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MeiraGTx beats Abeona Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Abeona Therapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, Abeona Therapeutics had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 6 mentions for Abeona Therapeutics and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.82 beat Abeona Therapeutics' score of 0.57 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals presently has a consensus price target of $19.60, indicating a potential upside of 62.79%. Abeona Therapeutics has a consensus price target of $19.33, indicating a potential upside of 257.36%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Oric Pharmaceuticals has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Abeona Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

Oric Pharmaceuticals' return on equity of -35.35% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Abeona Therapeutics	N/A	-41.69%	-30.36%

Abeona Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Abeona Therapeutics	$5.82M	53.15	$71.18M	-$1.09	N/A

Summary

Abeona Therapeutics beats Oric Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Abeona Therapeutics compare to Immatics?

Immatics (NASDAQ:IMTX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

In the previous week, Abeona Therapeutics had 5 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Abeona Therapeutics and 1 mentions for Immatics. Immatics' average media sentiment score of 1.87 beat Abeona Therapeutics' score of 0.57 indicating that Immatics is being referred to more favorably in the media.

Company	Overall Sentiment
Immatics	Very Positive
Abeona Therapeutics	Positive

64.4% of Immatics shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Abeona Therapeutics has lower revenue, but higher earnings than Immatics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	22.01	-$222.26M	-$1.86	N/A
Abeona Therapeutics	$5.82M	53.15	$71.18M	-$1.09	N/A

Abeona Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Abeona Therapeutics' return on equity of -41.69% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-495.71%	-47.41%	-39.45%
Abeona Therapeutics	N/A	-41.69%	-30.36%

Immatics has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

Immatics currently has a consensus target price of $20.60, indicating a potential upside of 134.36%. Abeona Therapeutics has a consensus target price of $19.33, indicating a potential upside of 257.36%. Given Abeona Therapeutics' higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Abeona Therapeutics beats Immatics on 10 of the 15 factors compared between the two stocks.

How does Abeona Therapeutics compare to MannKind?

Abeona Therapeutics (NASDAQ:ABEO) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, MannKind had 5 more articles in the media than Abeona Therapeutics. MarketBeat recorded 11 mentions for MannKind and 6 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.57 beat MannKind's score of 0.48 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abeona Therapeutics has higher earnings, but lower revenue than MannKind. MannKind is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	53.15	$71.18M	-$1.09	N/A
MannKind	$348.97M	3.46	$5.86M	-$0.13	N/A

Abeona Therapeutics currently has a consensus price target of $19.33, indicating a potential upside of 257.36%. MannKind has a consensus price target of $8.34, indicating a potential upside of 122.50%. Given Abeona Therapeutics' higher probable upside, equities analysts plainly believe Abeona Therapeutics is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Abeona Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of -11.21% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
MannKind	-11.08%	-11.21%	-6.31%

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by company insiders. Comparatively, 2.6% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Abeona Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, MannKind has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Summary

Abeona Therapeutics beats MannKind on 9 of the 16 factors compared between the two stocks.

Get Abeona Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABEO vs. The Competition

Export

Metric	Abeona Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$309.34M	$3.85B	$7.15B	$12.84B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-4.96	14.25	275.25	25.35
Price / Sales	53.15	1,412.41	644.34	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	1.84	15.15	10.36	6.21
Net Income	$71.18M	-$22.86M	$3.50B	$358.54M
7 Day Performance	-9.83%	-4.35%	-3.31%	-2.39%
1 Month Performance	-9.68%	-0.64%	-0.86%	-3.39%
1 Year Performance	-15.86%	40.78%	23.55%	8.81%

Abeona Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABEO Abeona Therapeutics	1.9281 of 5 stars	$5.41 -0.2%	$19.33 +257.4%	-15.9%	$309.34M	$5.82M	N/A	90
OMER Omeros	3.9178 of 5 stars	$18.95 flat	$38.00 +100.5%	+340.5%	$1.37B	N/A	14.80	210	Positive News Gap Up
MGTX MeiraGTx	4.2677 of 5 stars	$13.89 flat	$26.17 +88.4%	+68.1%	$1.33B	$81.39M	19.56	300	Positive News Gap Down
ORIC Oric Pharmaceuticals	2.7109 of 5 stars	$12.86 flat	$19.60 +52.4%	+11.7%	$1.33B	N/A	N/A	80
IMTX Immatics	3.3594 of 5 stars	$9.56 flat	$20.60 +115.5%	+51.0%	$1.31B	$54.60M	N/A	260

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABEO) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abeona Therapeutics (ABEO) Competitors

ABEO vs. OMER, MGTX, ORIC, IMTX, and MNKD

How does Abeona Therapeutics compare to Omeros?

Summary

How does Abeona Therapeutics compare to MeiraGTx?

Summary

How does Abeona Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Abeona Therapeutics compare to Immatics?

Summary

How does Abeona Therapeutics compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abeona Therapeutics (ABEO) Competitors

ABEO vs. OMER, MGTX, ORIC, IMTX, and MNKD

How does Abeona Therapeutics compare to Omeros?

Which has more volatility & risk, ABEO or OMER?

Do analysts rate ABEO or OMER?

Which has stronger valuation & earnings, ABEO or OMER?

Does the media refer more to ABEO or OMER?

Is ABEO or OMER more profitable?

Do institutionals and insiders believe in ABEO or OMER?

Summary

How does Abeona Therapeutics compare to MeiraGTx?

Do institutionals & insiders hold more shares of MGTX or ABEO?

Is MGTX or ABEO more profitable?

Which has preferable earnings and valuation, MGTX or ABEO?

Do analysts rate MGTX or ABEO?

Which has more volatility and risk, MGTX or ABEO?

Does the media favor MGTX or ABEO?

Summary

How does Abeona Therapeutics compare to Oric Pharmaceuticals?

Does the media favor ORIC or ABEO?

Do analysts recommend ORIC or ABEO?

Do insiders & institutionals hold more shares of ORIC or ABEO?

Which has more risk & volatility, ORIC or ABEO?

Is ORIC or ABEO more profitable?

Which has better valuation and earnings, ORIC or ABEO?

Summary

How does Abeona Therapeutics compare to Immatics?

Does the media refer more to IMTX or ABEO?

Do insiders and institutionals hold more shares of IMTX or ABEO?

Which has higher earnings & valuation, IMTX or ABEO?

Is IMTX or ABEO more profitable?

Which has more volatility & risk, IMTX or ABEO?

Do analysts recommend IMTX or ABEO?

Summary

How does Abeona Therapeutics compare to MannKind?

Does the media prefer ABEO or MNKD?

Which has stronger earnings and valuation, ABEO or MNKD?

Do analysts recommend ABEO or MNKD?

Is ABEO or MNKD more profitable?

Do institutionals & insiders believe in ABEO or MNKD?

Which has more risk and volatility, ABEO or MNKD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools